<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261923</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra CT 2010-020212-11</org_study_id>
    <nct_id>NCT01261923</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease</brief_title>
  <official_title>Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate whether liver patients may tolerate alitretinoin by comparing&#xD;
      metabolism in 8 such patients with the metabolism in 8 healthy controls&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to investigate whether liver patients may tolerate alitretinoin.&#xD;
&#xD;
      Toctino (alitretinoin) is a vitamin A like substance that has proven effective in the&#xD;
      treatment of specially hand eczema. The medicine is taken as capsules daily for up to 3&#xD;
      months. Toctino is currently only approved for patients with normal liver function, because&#xD;
      it has never been studied how drug metabolism and excretion occurs in liver disease patients.&#xD;
      This, however, the investigators want to examine in order to achieve an additional treatment&#xD;
      for patients with severe hand eczema and concomitant liver disease.&#xD;
&#xD;
      The study is a collaboration between dermatology and medical department, Gentofte Hospital&#xD;
      and University of Copenhagen, where blood and urine tests will be conducted. From the medical&#xD;
      department, 8 patients diagnosed with liver disease will be recruited. Patients should only&#xD;
      receive a single dose of Toctino (30 mg capsules). 20 blood samples and one urine sample will&#xD;
      be taken over the next 24 hours (approximately 250-300 ml) to measure the concentration of&#xD;
      Toctino in blood and urine. Moreover, the urine will be collected over 24 hours. Then the&#xD;
      investigators will recruit an 8-person control group that is matched according to gender, age&#xD;
      and weight. In this control group will take exactly the same samples. Based on determining&#xD;
      concentrations in blood and urine will be able to mathematically calculate how Toctino is&#xD;
      absorbed, distributed and excreted in liver disease patients in conjunction with a healthy&#xD;
      control group. The study will therefore help to determine what dose of Toctino that would be&#xD;
      preferable in liver disease patients.&#xD;
&#xD;
      The survey is estimated to be associated with a very low risk both for participating patients&#xD;
      and control group. Toctino is an approved drug and side effects occur almost exclusively in&#xD;
      long term treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The investigators wish to investigate whether the metabolism of alitretinoin differs between healthy controls and patients with moderate to severe hepatic disease</measure>
    <time_frame>2 years</time_frame>
    <description>The metabolism of alitretinoin will be examined by measuring blood concentrations after time: 0 , ¼, ½, ¾, 1, 1¼, 1½, 2, 2½, 3, 3½, 4, 5, 6, 8, 10, 12 and 24 hours.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Alitretinoin - Hepatic Insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alitretinoin - Hepatic Insufficiency Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metabolism of 30 mg alitretinoin single dose in 8 healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alitretinoin</intervention_name>
    <description>30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)</description>
    <arm_group_label>Alitretinoin - Hepatic Insufficiency</arm_group_label>
    <arm_group_label>Alitretinoin - Hepatic Insufficiency Controls</arm_group_label>
    <other_name>9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be medically stable for at least 1 month before the intake of 9-cis-RA.&#xD;
&#xD;
          2. There must be an ultrasound scan of liver and abdomen within the last 3 months (liver&#xD;
             size, ascites).&#xD;
&#xD;
          3. In women of childbearing age, there must be a negative pregnancy test, while that to&#xD;
             be used adequate contraception (the pill, coil or surgical sterilization) at least 1&#xD;
             month after taking the study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant deviations in routine blood tests (hematology, electrolytes and&#xD;
             kid-ney, urinalysis). Differences attributable to underlying liver disease are&#xD;
             excluded.&#xD;
&#xD;
          2. Encephalopathy (&gt; grade II)&#xD;
&#xD;
          3. Concomitant treatment with drugs predominantly metabolised in the liver by CYP3A4.&#xD;
&#xD;
          4. Clinically significant ECG changes, cardiovascular disease and AMI within the last 12&#xD;
             months&#xD;
&#xD;
          5. Affected renal function judged by Cockcroft-Gault formula.&#xD;
&#xD;
          6. Epilepsy or significant neurological disease that requires drug therapy.&#xD;
&#xD;
          7. History of cerebrovascular relapse&#xD;
&#xD;
          8. Esophagus bleeding&#xD;
&#xD;
          9. Severe ascites&#xD;
&#xD;
         10. HIV&#xD;
&#xD;
         11. Mental illness.&#xD;
&#xD;
         12. Active cancer&#xD;
&#xD;
         13. Pregnancy or pregnancy plan within 3 months.&#xD;
&#xD;
         14. Breastfeeding women.&#xD;
&#xD;
         15. Participation in other clinical projects.&#xD;
&#xD;
         16. Intake of clinical trial medication in the past month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Grønhøj, MD DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <last_update_submitted>January 26, 2013</last_update_submitted>
  <last_update_submitted_qc>January 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Frederik Grønhøj</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alitretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

